Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2007-01-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
i. NAS scores may indicate more than withdrawal. Conditions such as colic, reflux, or baseline irritability may influence the baseline scores. Decisions made based on the NAS scores should take into account these factors and the baseline for the infant.
b.Emergence of symptom, dosing, and initiation of treatment: Withdrawal is defined as at least 2 NAS scores \>8 or 1 NAS score \>12. Once withdrawal has emerged, the infant will be given: i. Phenobarbital 20 to 30 mg/kg to load divided in up to 3 doses over 24 hours and maintenance phenobarbital should be started at 2.5 mg/kg/dose administered Q 12h, 12 hours after the loading dose is ended. NAS scoring is continued and if scores remain \<8 for a minimum of 5 days after starting phenobarbital, the infant is eligible for discharge.
ii. If after phenobarbital treatment has been started, at least 2 NAS scores \>8 or 1 NAS score \>12, then a phenobarbital level will be drawn and a mini-load calculated to reach a level of 30 mg/dl. If withdrawal is not controlled or re-emerges after the mini-load dose, the infant will be randomized to one of the two arms of the study - methadone or dDTO.
iii. Twins will be randomized together to the same arm. iv. Randomization will be stratified into mothers on narcotic treatment \>3 months and those not in treatment or \<3 months. Randomization will be done in blocks of 10 for each stratum.
v. For both drugs, the neonatal preparation will be used. vi. The following is a dosing guide for methadone:
1. The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours - standardized eventually to 0900 and 2100.
2. For the first 24 hours, doses will be prescribed every 6 hours for 4 doses, using a sliding scale in response to the last NAS score:
NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose \>16 0.15 mg/kg/dose
3. Maximum loading dose of methadone will be 0.15 mg/kg/dose Q 6 hour
4. After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. Subsequently, PRN doses of 0.05 mg/kg/dose may be given every 6 hours for scores \>8 X 2 and added to the next 24 hour's doses, divided every 12 hours, until NAS scores are consistently \<8 for 48 hours.
5. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm.
vii. The following is a dosing guide for dDTO:
1. The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours - standardized eventually to 0400, 0800, 1200, 1600, 2000, 0000.
2. The starting dose is determined by using a sliding scale in response to the last NAS score before starting:
NAS Score dDTO dose 8-11 0.1 mg/kg/day 12-15 0.15 mg/kg/day \>16 0.2 mg/kg/day
For next day, the maintenance dose will return to the previous dose and given in 6 divided doses given Q 4 hours.
iv. For either methadone or dDTO, dosing will be held at this level and weaning will be resumed when the infant has NAS scores \<8 for 48 hours.
e. Holding of doses: Methadone or dDTO will be held for poor feeding, respiratory depression, or somnolence at any time in the protocol.
f. Behavioral assessment: Behavioral assessment will be done by two methods. The first by actigraphy and the second by NINS, both during the second week of weaning. The latter will be done prior to a scheduled phenobarbital dose.
g. Formula: A 24 kcal/ounce formula should be fed initially using either standard formula or by adding breast milk fortifier. During the weaning period, when weight gain is \>30 grams/day for at least 2 days, formula will be changed to 20 kcal/ounce and weight gain monitored. If not sustained, then formula should be changed back to 24 kcal/ounce.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 (Phenobarbital and Methadone)
The following is a dosing guide for methadone:
1. The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.
2. For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:
NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose
≥16 0.15 mg/kg/dose
3. Maximum dose of methadone will be 0.15 mg/kg/dose.
4. After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently \<8 for 48 hours.
5. If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm.
Methadone
Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
2 (Phenobarbital and Diluted Deodorized Tincture of Opium)
The following is a dosing guide for dDTO:
1. The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.
2. The starting dose will be determined using a sliding scale in response to the last NAS score before starting.
NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day
≥16 0.8 mg/kg/day
3. The maximum dose of DTO will be 0.8 mg/kg/day.
4. After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.
5. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm.
Diluted Deodorized Tincture of Opium
Concentration is 1:24 dilution for a concentration of 0.4%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methadone
Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
Diluted Deodorized Tincture of Opium
Concentration is 1:24 dilution for a concentration of 0.4%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestation \>=35 weeks at entry defined by best obstetrical and physical exam criteria, AND
* Medically stable condition, other than in opioid withdrawal, in the opinion of the attending neonatologist, AND EITHER,
* Meconium or urine drug screen positive for opioids on mother or newborn, OR
* Known maternal prescription of opioids for chronic pain management during at least the last trimester of pregnancy, OR
* Known maternal prescription of opioids for treatment of addiction, OR
* Suspected or admitted abuse with opioid drugs
* Infants of mothers with a medical or psychiatric diagnosis will not be excluded, unless the maternal diagnosis precludes informed consent
Exclusion Criteria
* Hypoglycemia, hypomagnesaemia, or hypocalcaemia until corrected.
* Serious medical illness such as sepsis, pneumonia, hyperthyroidism, meningitis, intracranial hemorrhage, perinatal depression, or respiratory failure requiring admission to the NICU.
* Evidence of major congenital anomalies or genetic syndromes that impact the neonatal course.
1 Day
6 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eastern Maine Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mark S Brown, MD
Chief of Pediatric Service, Neonatalogy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark S. Brown, MD
Role: PRINCIPAL_INVESTIGATOR
Eastern Maine Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastern Maine Medical Center
Bangor, Maine, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zankl A, Martin J, Davey JG, Osborn DA. Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021 Jul 7;7(7):CD002059. doi: 10.1002/14651858.CD002059.pub4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-2-M-107
Identifier Type: -
Identifier Source: org_study_id